| Website | comentis.com |
| Category | BioTech |
| Phone | 650-869-7600 |
| press@comentis.com | |
| Employees | |
| Founded | 2004 |
| Description | Neurovascular disease research |
| TOTAL | $32M |
| FUNDING TOTAL | $32M |
| Series C, 12/07 Wellington Partners | $12M |
| Series D, 6/08 | $20M |
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer’s disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
